CHICAGO, May 8, 2023 /PRNewswire/ -- The humanized mouse and rat model industry is expected to witness significant growth in the near future. These models are essential tools in biomedical research and drug development, allowing scientists to better understand human diseases and evaluate the efficacy and safety of potential treatments. Humanized mouse and rat models are created by introducing human genes, cells, or tissues into the animal models, enabling the simulation of human physiological and pathological processes. With advancements in gene-editing technologies like CRISPR-Cas9, the creation of more precise and sophisticated humanized models is becoming possible. This opens up new avenues for studying complex diseases, such as cancer, autoimmune disorders, and infectious diseases, and facilitates the development of targeted therapies. The use of humanized models in preclinical studies can help accelerate the drug discovery process, reduce costs, and improve the success rates of clinical trials. As a result, the humanized mouse and rat model industry is poised to play a pivotal role in advancing biomedical research and personalized medicine in the near future.

MarketsandMarkets_Logo

Humanized Mouse and Rat Model Marketin terms of revenue was estimated to be worth $237 million in 2022 and is poised to reach $338 million by 2027, growing at a CAGR of 7.4% from 2022 to 2027 according to a new report by MarketsandMarkets. Factors such as advances in genomics, proteomics, and metabolomics; completion of the human genome map; the development of targeted diagnostics and therapeutics; and the growing emphasis on health, wellness, and preventive measures are driving the demand for personalized medicine and, subsequently the demand for relevant humanized mouse and rat research models. Also, grants from government and private organizations for cancer research have also supported the development of humanized models in oncology. For instance, in 2020, the US NIH funded a large-scale project to find treatments for rare genetic diseases with a five-year grant of USD 10,625,000 to The Jackson Laboratory Center for Precision Genetics. In the same year, The Jackson Laboratory received a grant from the NIH for its Mouse Mutant Resource and Research Centers (MMRRC) program, established in 2009. The new grant provides a total of USD 6,119,082 over five years to the MMRRC. With such grants and funding from the government and private sectors, the demand for humanized mouse models is expected to increase.

Story continues

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131763955

Browse in-depth TOC on "Humanized Mouse and Rat Model Market"

140 - Tables27 - Figures177 - Pages

Humanized Mouse and Rat Model MarketScope:

Report Coverage

Details

Market Revenue in 2022

$237 million

Estimated Value by 2027

$338 million

Growth Rate

Poised to grow at a CAGR of 7.4%

Market Size Available for

2020-2027

Forecast Period

20222027

Forecast Units

Value (USD Million)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

Segments Covered

Type, Application, End User, and Region

Geographies Covered

North America, Europe, Asia Pacific, Latin America (LATAM) and Middle East and Africa (MEA)

Report Highlights

Updated financial information / product portfolio of players

Key Market Opportunities

Rising demand for humanized PDX models

Key Market Drivers

Increasing research activities using humanized models

The genetic humanized mouse model segment accounted for the largest share of the humanized mouse model segment in the humanized mouse and rat model market in 2021.

Based on type, the humanized mouse and rat model market has been segmented into humanized mouse models and humanized rat models. The humanized mouse models' segment is further divided into genetic humanized mouse models and cell-based humanized mouse models. In 2021, genetic humanized mouse segment accounted for the largest share of humanized mouse model market. Advances in genetic engineering technologies, such as gene targeting and gene editing, have led to the development of genetically engineered humanized mouse models that serve as an important tool for a variety of research applications. In addition to the widespread use of these mice in diverse research areas, the emerging CRISPR technology, increasing focus on personalized medicine with the continuous introduction of new models, and various licensing agreements are expected to drive market growth.

The immunology and infectious diseases segment accounted for the second largest share of the application segment in the humanized mouse and rat model market in 2021.

Based on application, the humanized mouse and rat model market is segmented into oncology, immunology and infectious diseases, neuroscience, Hematopoiesis, toxicology, and other applications. Immunology and Infectious diseases segment accounted for the second largest share of the humanized mouse and rat model market in 2021. Mouse models are used in immunology and inflammation studies as they help assess the physiological relevance of an experimental finding. The use of mouse models allows suitable alterations in the mouse genome at random or in specific regions, enabling a detailed study of immunological processes. They also assist in identifying the function of newly identified surface receptors in host defense as well as the developmental consequences of a disturbed signaling pathway or removing a transcription factor. Such mouse models are developed on a large scale in laboratories or institutes and are used for application in Immunology and Infectious diseases segment. Thus, making it the second largest segment in the market.

The Asia Pacific region is the fastest-growing region of the humanized mouse and rat model market in 2021.

Based on the region, the humanized mouse and rat model market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is estimated to register the highest growth during the forecast period. Global pharmaceutical firms are increasingly moving to APAC to tap into its thriving market and lower their production costs by shifting manufacturing and laboratory testing to the region. The rapidly increasing demand for the outsourcing of quality control safety testing (including efficacy testing) in countries such as China, India, Japan, and Singapore is expected to drive market growth in the Asia Pacific during the forecast period.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=131763955

Humanized Mouse and Rat Model Market Dynamics:

Drivers:

Increasing research activities using humanized models

Rising demand for personalized medicine

Continuous support and initiatives from government and private sectors for cancer research

Growing R&D activities in pharmaceutical and biotechnology sectors

Restraints:

High cost of custom humanized models

Laws and regulations for ethical use of animal models in research

Opportunities:

Rising demand for humanized PDX models

Emergence of CRISPR as a powerful tool in biomedical research

Rising demand for humanized rat models

Challenges:

Alternatives for animal testing

Limitations of humanized mouse models

Key Market Players:

Key players in the humanized mouse and rat model Market include Charles River Laboratories International, Inc. (US), The Jackson Laboratory (JAX) (US), Taconic Biosciences, Inc. (US), Crown Bioscience (US), and Envigo (US).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=131763955

Recent Developments:

In January 2022, Taconic Biosciences, Inc. (US) launched the huNOG-EXL EA (early access) humanized immune system (HIS) mouse.

In October 2021, The Jackson Laboratory (US) acquired RMS Business of Charles River Laboratories Japan, Inc. (Japan) which is Charles River Laboratories Japan's Research Models & Services (RMS) business as a wholly-owned subsidiary.

In September 2021, Biocytogen (US) collaborated with Envigo (US) in order to support the research applications of the triple immunodeficient B-NDG mouse. Envigo is the exclusive provider of B-NDG mice in the US, Europe, and certain APAC regions.

In March 2021, Charles River Laboratories International, Inc. (US) acquired Cognate BioServices, Inc. (US) a cell and gene therapy contract development and manufacturing organization (CDMO) offering comprehensive manufacturing solutions for cell therapies. The acquisition expanded Charles River's broad capabilities across the major CDMO platforms for cell and gene therapies.

Humanized Mouse and Rat Model Market Advantages:

Enhanced translatability: Humanized mouse and rat models closely mimic human physiology and disease conditions, allowing for more accurate translation of research findings to human patients. This increases the likelihood of successful translation from preclinical studies to clinical trials.

Study of human-specific diseases: Humanized models enable the study of human-specific diseases that cannot be effectively studied in traditional animal models. These models provide insights into the mechanisms of diseases such as cancer, autoimmune disorders, and infectious diseases, leading to the development of targeted therapies.

Evaluation of drug efficacy and safety: Humanized models allow researchers to evaluate the efficacy and safety of potential drug candidates in a more relevant and predictive manner. This leads to more informed decision-making in drug development, reducing the likelihood of failures in later stages of clinical trials.

Personalized medicine advancements: Humanized models enable the exploration of personalized medicine approaches by allowing researchers to assess the response of specific patient populations to different therapies. This can aid in the development of tailored treatments and improve patient outcomes.

Reduction in animal usage: By using humanized models, researchers can minimize the reliance on traditional animal models, reducing the number of animals used in research studies while obtaining more clinically relevant data.

Humanized Mouse and Rat Model Market - Report Highlights:

Refinements in the chapters of the humanized mouse and rat model market

Updated financial information/service portfolio of players

Updated market developments of profiled players

Related Reports:

Mice Model Market- Global Forecasts to 2028

CRO Services Market- Global Forecasts to 2028

PDX Models Market- Global Forecasts to 2026

In Vivo Toxicology Market- Global Forecasts to 2025

Life Science Instrumentation Market- Global Forecasts to 2025

About MarketsandMarkets:

MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit http://www.MarketsandMarkets.comor follow us on Twitter, LinkedInand Facebook.

Contact:Mr. Aashish MehraMarketsandMarkets INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: sales@marketsandmarkets.comResearch Insight: https://www.marketsandmarkets.com/ResearchInsight/humanized-mouse-model-market.aspVisit Our Website: https://www.marketsandmarkets.com/Content Source: https://www.marketsandmarkets.com/PressReleases/humanized-mouse-model.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

Cision

View original content:https://www.prnewswire.com/news-releases/humanized-mouse-and-rat-model-market-worth-338-million--marketsandmarkets-301818314.html

SOURCE MarketsandMarkets

See the original post:
Humanized Mouse and Rat Model Market worth $338 million | MarketsandMarkets - Yahoo Finance